# EntityRisk — PROVEN™ Health Economic Modeling Platform for Pharmaceutical Companies

> EntityRisk combines health economics expertise with PROVEN™, an advanced modeling platform built for pharmaceutical companies. PROVEN™ uses machine learning and Bayesian methods to predict health outcomes, optimize value-based pricing, and justify evidence investments across multiple value frameworks.

> The pages and posts below cover EntityRisk's scientific methodology, PROVEN™ platform capabilities, health economics frameworks, and biopharma industry applications. Content is intended for pharmaceutical companies, health economists, and payers navigating drug pricing, market access, and outcomes modeling. EntityRisk serves 10 of the top 20 biopharma companies globally.

---


## Pages

- [EntityRisk](https://entityrisk.com/): EntityRisk is focused on enabling financial innovation in healthcare by addressing the full spectrum of uncertainty-related drug pricing and access...
- [IRA Drug Price Negotiation Modeling](https://entityrisk.com/ira-drug-price-negotiation/): IRA Drug Price Negotiation Modeling for HEOR & Market Access Teams Translate Inflation Reduction Act negotiation mechanics into transparent, scenario-based...
- [Pharma Value Assessment Modeling](https://entityrisk.com/pharma-value-assessment/): Pharma Value Assessment Modeling for HEOR & Market Access Teams Translate value assessment frameworks into transparent, scenario-based impact models, so...
- [Landing Page - ISPOR 2026](https://entityrisk.com/news-events/landing-page-ispor-2026/): ISPOR 2026 May 17-20, 2026 Pennsylvania Convention Center, Philadelphia, PA Join EntityRisk and industry leaders for an exclusive forum on...
- [MFN Drug Pricing Modeling](https://entityrisk.com/mfn-drug-pricing-modeling/): MFN Drug Pricing Modeling for HEOR & Market Access Teams Translate Most Favored Nation (MFN) pricing concepts into transparent, scenario-based...
- [ICER Cost Effectiveness Analysis](https://entityrisk.com/icer-cost-effectiveness-analysis/): ICER Cost Effectiveness Analysis for HEOR & Market Access Teams Translate ICER cost effectiveness analysis into transparent, scenario-based impact models—so...
- [Access Forum 2026](https://entityrisk.com/news-events/access-forum-2026/): ACCESS Forum 2026 February 11th-13th, 2026 Roosevelt Hotel, New Orleans Join EntityRisk and industry leaders for an exclusive forum on...
- [Contact](https://entityrisk.com/contact/): Speak with a Health Economics Expert Across recent ISPOR surveys, >60 % of respondents cited access, ownership, and transparency barriers...
- [Landing](https://entityrisk.com/health-economics-value-assessments/): 10 of the 20 Top Pharmaceutical Companies That’s who trusts EntityRisk’s combination of globally recognized health economics and policy expertise...
- [Get It Right](https://entityrisk.com/getitright/): Pressure-test your value before the market does. With PROVEN™ get it right the first time, fast Built for Market Access,...
- [Overview](https://entityrisk.com/overview/): PROVEN™ Software for an Uncertain World The Problem One of the biggest risks drug innovators face is realizing the complete...
- [ValueML](https://entityrisk.com/valueml/): Case Study PROVEN™ Estimated Value-Based Prices 3x Higher than Traditional Methods Background Our client was preparing to launch an innovative...
- [EvidenceML](https://entityrisk.com/evidenceml/): Case Study PROVEN™ Supported Evidence Prioritization in Advance of IRA Negotiations Background Our client was preparing for the possibility of...
- [PriceML](https://entityrisk.com/priceml/): Case Study EntityRisk Out-Performed Wall Street in Predicting Launch Price Background EntityRisk quantified the commercial value of Madrigal Pharmaceuticals’ (MDGL)...
- [News](https://entityrisk.com/news-events/news/): Latest news from across the industry
- [Events](https://entityrisk.com/news-events/events/): Latest events from across the industry
- [News & Events](https://entityrisk.com/news-events/): Events & News Latest events and news from across the industry Events More Events Latest News More News
- [PROVEN™ Perspectives](https://entityrisk.com/thought-leadership/proven-perspectives/): Latest news and insights from across the country All Proven™ Perspectives Webcasts White Papers
- [Webcasts](https://entityrisk.com/thought-leadership/webcasts/): Latest new and insights from across the country All Proven™ Perspectives Webcasts White Papers
- [White Papers](https://entityrisk.com/thought-leadership/white-papers/): Latest new and insights from across the country All Proven™ Perspectives Webcasts White Papers
- [Opt-out preferences](https://entityrisk.com/opt-out-preferences/)
- [Jobs](https://entityrisk.com/careers-jobs/): Jobs At EntityRisk, we are always looking for passionate, dynamic and highly skilled individuals to join the team and take...
- [Thought Leadership](https://entityrisk.com/thought-leadership/): Latest news and insights from across the country All Proven™ Perspectives Webcasts White Papers
- [Team](https://entityrisk.com/about-us/): About Us EntityRisk was founded by three leading PhD health economists, Dana Goldman, Darius Lakdawalla, and Neal Masia, combining decades...

---


## Posts

- [White Paper: Getting the Math Right When Measuring the Value of New Medicines](https://entityrisk.com/white-papers/getting-the-math-right-when-measuring-the-value-of-new-medicines/)
- [PROVEN™ Perspectives Blog #4: Quantifying the Societal Value Drivers of neffy® with PROVEN™](https://entityrisk.com/proven-perspectives/quantifying-societal-value-drivers-of-neffy-with-proven/): Eric Karas, Neal MasiaAs many as 2 in 3 children and 1 in 4 adults experience needle phobia, introducing significant...
- [PROVEN™ Perspectives Blog #3: Analyzing Variable Importance for Generalized Cost-effectiveness Analysis with PROVEN™](https://entityrisk.com/proven-perspectives/analyzing-variable-importance-gcea-proven/): Elmar Alizadeh, Stella Arndorfer, Ali Ruderian, Devin IncertiSimulation models often map hundreds of inputs to outcomes in complex ways, making...
- [PROVEN™ Perspectives Blog #1: Welcome to PROVEN™ Perspectives](https://entityrisk.com/proven-perspectives/welcome-to-proven-perspectives/): Welcome to PROVEN™ Perspectives, the new blog-style section of our website highlighting the ideas, methods, and software tools developed by...
- [PROVEN™ Perspectives Blog #2: Automating Dynamic Pricing and Stacked Cohorts with PROVEN™](https://entityrisk.com/proven-perspectives/automating-dynamic-pricing-and-stacked-cohorts-with-proven/): Devin Incerti, Elmar Alizadeh, Ali Ruderian, Jeff Sullivan, Darius Lakdawalla Introduction Generalized cost-effectiveness analysis (GCEA) has grown in popularity over...
- [Webcast Episode 4: Addressing Uncertainty in Today's Bio-pharma Market](https://entityrisk.com/webcasts/webcast-episode-4/): Today’s bio-pharma market is characterized by escalating uncertainty around policy-making and the Inflation Reduction Act. How are CEOs and investors...
- [Webcast Episode 3: A Bio-pharma CFO's Playbook for Accurate Forecasts](https://entityrisk.com/webcasts/webcast-episode-3/): How do bio-pharma CFOs deliver accurate forecasts given the uncertainty ahead? Pfizer’s former CFO, Frank D’Amelio, shares how he developed...
- [Getting The Math Right When Measuring The Value of New Medicines](https://entityrisk.com/proven-perspectives/white-paper-getting-the-math-right-new-medicines/): Cost-effectiveness analysis (CEA) is commonly used to inform the assessment of value from new healthcare technologies. However, traditional CEA methods...
- [EntityRisk Launches PROVEN™ Platform](https://entityrisk.com/proven-perspectives/entityrisk-launches-proven-platform/): EntityRisk today announced the launch of the PROVEN™ software platform for biopharma innovators and investors.
- [Generalized Risk-Adjusted Cost-Effectiveness (GRACE) aligns value assessment with the preferences and needs of real-world patients](https://entityrisk.com/proven-perspectives/grace-aligns-value/): Generalized Risk-Adjusted Cost-Effectiveness (GRACE) aligns value assessment with the preferences and needs of real-world patients. Evidence has accumulated that traditional...
- [ISPOR Europe Poster: Generalizing the Distribution and Dynamics of Health Outcomes in Clinical Trials for Novel Treatment of Rare Disease](https://entityrisk.com/proven-perspectives/ispor-europe-poster/): Objective: Challenges: Methods: Fill out the form below to download the poster: * By downloading, you are agreeing to be...
- [Webcast Episode 2: What a step change in the speed and quality of cost effectiveness analysis will impact](https://entityrisk.com/webcasts/webcast-episode-2/): Watch the webcast recording below featuring award-winning health economist Darius Lakdawalla and data scientist Devin Incerti as they break down...
- [Webcast Episode 1: How to determine commercial value in a downturn](https://entityrisk.com/webcasts/webcast-episode-1/): How can you predict how payers around the world will value new therapies when caution remains the dominant theme of...
- [White Paper: Meeting the Analytic Challenges of Value-Based Agreements in Life Sciences](https://entityrisk.com/white-papers/white-paper-meeting-challenges-value-based-agreements/): Uncertainty about the real-world effectiveness and value of a new product or a new indication can hinder market access, especially...

---


## Team Members

- [Sarah Dusse](https://entityrisk.com/team_members/sarah-dusse/)
- [Sophia Praggastis](https://entityrisk.com/team_members/sophia-praggastis/)
- [Kyle Williams](https://entityrisk.com/team_members/kyle-williams/)
- [Katie Buss](https://entityrisk.com/team_members/katie-buss/)
- [Jireh Huang](https://entityrisk.com/team_members/jireh-huang/)
- [Aaron Lucas](https://entityrisk.com/team_members/aaron-lucas/)
- [Jim Maffezzoli](https://entityrisk.com/team_members/jim-maffezzoli/)
- [Ryan Rava](https://entityrisk.com/team_members/ryan-rava/)
- [Stephen Smith](https://entityrisk.com/team_members/stephen-smith/)
- [Wissam Afyouni](https://entityrisk.com/team_members/wissam-afyouni/)
- [Barnaly Rashid](https://entityrisk.com/team_members/barnaly-rashid/)
- [Alex Chouraqui](https://entityrisk.com/team_members/alex-chouraqui/)
- [Alison Ruderian](https://entityrisk.com/team_members/alison-ruderian/)
- [Ellie Crecelius](https://entityrisk.com/team_members/ellie-crecelius/)
- [Darren Filson](https://entityrisk.com/team_members/darren-filson/)
- [Edward Vytlacil](https://entityrisk.com/team_members/edward-vytlacil/)
- [Sari Tower](https://entityrisk.com/team_members/sari-tower/)
- [Jeffrey Sullivan](https://entityrisk.com/team_members/jeffrey-sullivan/)
- [Seth Seabury](https://entityrisk.com/team_members/seth-seabury/)
- [Charles E. Phelps, PhD](https://entityrisk.com/team_members/charles-e-phelps-phd/)
- [Dana Panzer](https://entityrisk.com/team_members/dana-panzer/)
- [Leonardo Ortega](https://entityrisk.com/team_members/leonardo-ortega/)
- [David Moules](https://entityrisk.com/team_members/david-moules/)
- [Andrew Morris](https://entityrisk.com/team_members/andrew-morris/)
- [Neal Masia, PhD](https://entityrisk.com/team_members/neal-masia-phd/)
- [Darius Lakdawalla, PhD](https://entityrisk.com/team_members/darius-lakdawalla-phd/)
- [Jeff Kindler](https://entityrisk.com/team_members/jeff-kindler/)
- [David C. Grabowski, PhD](https://entityrisk.com/team_members/david-c-grabowski-phd/)
- [Devin Incerti, PhD](https://entityrisk.com/team_members/devin-incerti-phd/)
- [Dana Goldman, PhD](https://entityrisk.com/team_members/dana-goldman-phd/)
- [Perry Goldberg, JD](https://entityrisk.com/team_members/perry-goldberg-jd/)
- [Katie Everson](https://entityrisk.com/team_members/katie-everson/)
- [Frank D’Amelio](https://entityrisk.com/team_members/frank-damelio/)
- [Alice Chen](https://entityrisk.com/team_members/alice-chen/)
- [Katharine Batt, MD](https://entityrisk.com/team_members/katharine-batt-md/)
- [Elmar R. Alizadeh, PhD](https://entityrisk.com/team_members/elmar-r-alizadeh-phd/)
- [Stella Arndorfer](https://entityrisk.com/team_members/stella-arndorfer/)

---


## News and Events

- [Towards More Trustworthy Models: ISPOR - SMDM Model Validation II Joint Task Force Preliminary Recommendations](https://entityrisk.com/news_and_events/towards-more-trustworthy-models-ispor-smdm-model-validation-ii-joint-task-force-preliminary-recommendations/)
- [ISPOR Fast Facts: The Global Pricing Pendulum: Value Assessment, and the Future of Pharmaceutical Innovation in A World Driven by Trade Incentives](https://entityrisk.com/news_and_events/ispor-fast-facts-the-global-pricing-pendulum-value-assessment-and-the-future-of-pharmaceutical-innovation-in-a-world-driven-by-trade-incentives/)
- [ISPOR Plenary: US Pharmaceutical Policy: Leading or Following?](https://entityrisk.com/news_and_events/ispor-plenary-us-pharmaceutical-policy-leading-or-following/)
- [ISPOR Workshop: HEOR as a Compass, Not a Roadblock: How and When Development-Stage Biotech Companies Should Leverage HEOR](https://entityrisk.com/news_and_events/ispor-workshop-heor-as-a-compass-not-a-roadblock-how-and-when-development-stage-biotech-companies-should-leverage-heor/)
- [ISPOR Issue Panel: Whose Preferences Should Govern Health Technology Adoption? Debating the Foundations and the Future of Value Assessment](https://entityrisk.com/news_and_events/ispor-issue-panel-whose-preferences-should-govern-health-technology-adoption-debating-the-foundations-and-the-future-of-value-assessment/)
- [ISPOR Plenary: Innovation Under Pressure: How Will U.S. Drug Policy Reshape Innovation, Evidence, and Access Globally?](https://entityrisk.com/news_and_events/ispor-plenary-innovation-under-pressure-how-will-u-s-drug-policy-reshape-innovation-evidence-and-access-globally/)
- [ISPOR Issue Panel: Evolving Approaches to Measuring Benefits in Economic Evaluation](https://entityrisk.com/news_and_events/ispor-issue-panel-evolving-approaches-to-measuring-benefits-in-economic-evaluation/)
- [ISPOR 2026](https://entityrisk.com/news_and_events/ispor-2026/)
- [Access Forum 2026](https://entityrisk.com/news_and_events/access-forum-2026/)
- [Cleo Diagnostics commences Health Economic Study to support U.S. market entry](https://entityrisk.com/news_and_events/cleo-diagnostics-commences-health-economic-study-to-support-u-s-market-entry/): Partnership with EntityRisk to provide evidence-based insight into the economic value of Cleo’s Ovarian Cancer Pre-Surgical Test in the U....
- [ISPOR Plenary Session: Drug Price Controls—What Are the Unintended Consequences to Innovation?](https://entityrisk.com/news_and_events/plenary-session-drug-price-controls-what-are-the-unintended-consequences-to-innovation/)
- [ISPOR Session: Valuing Health: The Generalized Risk Adjusted Cost-Effectiveness (GRACE) Model](https://entityrisk.com/news_and_events/valuing-health-the-generalized-risk-adjusted-cost-effectiveness-grace-model-at-ispor/)
- [ISPOR 2025](https://entityrisk.com/news_and_events/ispor-2025/)
- [ISPOR Session: How Should Health Economists and Health Policymakers Measure the Costs of Inequality?](https://entityrisk.com/news_and_events/ispor-session-how-should-health-economists-and-health-policymakers-measure-the-costs-of-inequality/)
- [ISPOR Session: Challenges in the Implementation of Generalized Cost-Effectiveness Analysis (GCEA): Debating a Path Forward](https://entityrisk.com/news_and_events/ispor-session-challenges-in-the-implementation-of-generalized-cost-effectiveness-analysis-gcea-debating-a-path-forward/)
- [The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute](https://entityrisk.com/news_and_events/the-comparative-health-outcomes-policy-and-economics-choice-institute/)
- [ISPOR Session: Applied Cost-Effectiveness Modeling With R](https://entityrisk.com/news_and_events/applied-cost-effectiveness-modeling-with-r-at-ispor/)
- [Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best Practices](https://entityrisk.com/news_and_events/valuing-the-societal-impact-ofmedicines-and-other-healthtechnologies-a-user-guideto-current-best-practices/): Establishing a floor price mechanism would protect valuable innovation
- [JPMorgan Hosts First Major Healthcare Gathering Since Death of United Healthcare’s CEO](https://entityrisk.com/news_and_events/jpmorgan-hosts-first-major-healthcare-gathering-since-death-of-united-healthcares-ceo/): Industry leaders attending will see heightened security all around
- [Medicare Drug Price Explanations Shed Some Light on Future Talks](https://entityrisk.com/news_and_events/medicare-drug-price-explanations-shed-some-light-on-future-talks/): Medicare agency releases hundreds of pages of data, other info
- [Medicare drug price negotiations need something new: a floor](https://entityrisk.com/news_and_events/medicare-drug-pricenegotiations-need-something-new-a-floor/): Establishing a floor price mechanism would protect valuable innovation

---

#
# Detailed Content


## Pages

- Published: 2026-03-22
- Modified: 2026-03-27
- URL: https://entityrisk.com/
EntityRisk is focused on enabling financial innovation in healthcare by addressing the full spectrum of uncertainty-related drug pricing and access challenges. Our data-driven solutions address the full spectrum of risk considerations ranging from the uncertainty of drug pricing and access to the uncertainty in real-world effectiveness, utilization, and value. EntityRisk is a world-class team of economists, data scientists, software engineers, market access, finance professionals, and cutting-edge academic experts.

---

- Published: 2026-03-06
- Modified: 2026-03-06
- URL: https://entityrisk.com/ira-drug-price-negotiation/
---

- Published: 2026-03-06
- Modified: 2026-03-06
- URL: https://entityrisk.com/pharma-value-assessment/
---

- Published: 2026-02-24
- Modified: 2026-03-12
- URL: https://entityrisk.com/news-events/landing-page-ispor-2026/
---

- Published: 2026-02-23
- Modified: 2026-02-23
- URL: https://entityrisk.com/mfn-drug-pricing-modeling/
---

- Published: 2026-02-23
- Modified: 2026-02-24
- URL: https://entityrisk.com/icer-cost-effectiveness-analysis/
---

- Published: 2026-01-26
- Modified: 2026-01-29
- URL: https://entityrisk.com/news-events/access-forum-2026/
---

- Published: 2026-01-13
- Modified: 2026-02-27
- URL: https://entityrisk.com/contact/
---

- Published: 2025-12-22
- Modified: 2026-01-16
- URL: https://entityrisk.com/health-economics-value-assessments/
---

- Published: 2025-05-12
- Modified: 2026-02-09
- URL: https://entityrisk.com/getitright/
---

- Published: 2025-05-12
- Modified: 2026-03-17
- URL: https://entityrisk.com/overview/
---

- Published: 2025-05-12
- Modified: 2026-03-17
- URL: https://entityrisk.com/valueml/
---

- Published: 2025-05-12
- Modified: 2026-03-17
- URL: https://entityrisk.com/evidenceml/
---

- Published: 2025-05-12
- Modified: 2026-03-17
- URL: https://entityrisk.com/priceml/
---

- Published: 2025-02-28
- Modified: 2026-03-17
- URL: https://entityrisk.com/news-events/news/
---

- Published: 2025-02-28
- Modified: 2026-03-17
- URL: https://entityrisk.com/news-events/events/
---

- Published: 2025-02-22
- Modified: 2026-03-20
- URL: https://entityrisk.com/news-events/
---

- Published: 2025-02-19
- Modified: 2026-03-17
- URL: https://entityrisk.com/thought-leadership/proven-perspectives/
---

- Published: 2025-02-19
- Modified: 2026-03-17
- URL: https://entityrisk.com/thought-leadership/webcasts/
---

- Published: 2025-02-19
- Modified: 2026-03-17
- URL: https://entityrisk.com/thought-leadership/white-papers/
---

- Published: 2024-11-13
- Modified: 2024-11-13
- URL: https://entityrisk.com/opt-out-preferences/
---

- Published: 2024-03-04
- Modified: 2024-06-20
- URL: https://entityrisk.com/careers-jobs/
---

- Published: 2023-08-11
- Modified: 2026-03-17
- URL: https://entityrisk.com/thought-leadership/
---

- Published: 2023-08-09
- Modified: 2026-03-19
- URL: https://entityrisk.com/about-us/
---


---


## Posts

- Published: 2025-06-09
- Modified: 2025-06-13
- URL: https://entityrisk.com/proven-perspectives/quantifying-societal-value-drivers-of-neffy-with-proven/
- Categories: PROVEN™ Perspectives
---

- Published: 2025-03-11
- Modified: 2025-03-25
- URL: https://entityrisk.com/proven-perspectives/analyzing-variable-importance-gcea-proven/
- Categories: PROVEN™ Perspectives
---

- Published: 2025-01-09
- Modified: 2025-03-04
- URL: https://entityrisk.com/proven-perspectives/welcome-to-proven-perspectives/
- Categories: PROVEN™ Perspectives
---

- Published: 2025-01-09
- Modified: 2025-05-20
- URL: https://entityrisk.com/proven-perspectives/automating-dynamic-pricing-and-stacked-cohorts-with-proven/
- Categories: PROVEN™ Perspectives
---

- Published: 2023-11-14
- Modified: 2023-11-14
- URL: https://entityrisk.com/webcasts/webcast-episode-4/
- Categories: Webcasts
---

- Published: 2023-11-03
- Modified: 2023-11-03
- URL: https://entityrisk.com/webcasts/webcast-episode-3/
- Categories: Webcasts
How do bio-pharma CFOs deliver accurate forecasts given the uncertainty ahead? Pfizer’s former CFO, Frank D’Amelio, shares how he developed his playbook.

---

- Published: 2023-09-15
- Modified: 2025-03-05
- URL: https://entityrisk.com/proven-perspectives/white-paper-getting-the-math-right-new-medicines/
- Categories: PROVEN™ Perspectives
---

- Published: 2023-09-13
- Modified: 2023-09-13
- URL: https://entityrisk.com/proven-perspectives/entityrisk-launches-proven-platform/
- Categories: PROVEN™ Perspectives
EntityRisk today announced the launch of the PROVEN™ software platform for biopharma innovators and investors.

---

- Published: 2023-08-14
- Modified: 2023-08-14
- URL: https://entityrisk.com/proven-perspectives/grace-aligns-value/
- Categories: PROVEN™ Perspectives
---

- Published: 2023-07-14
- Modified: 2025-03-05
- URL: https://entityrisk.com/proven-perspectives/ispor-europe-poster/
- Categories: PROVEN™ Perspectives
---

- Published: 2023-02-07
- Modified: 2025-04-01
- URL: https://entityrisk.com/webcasts/webcast-episode-2/
- Categories: Webcasts
---

- Published: 2023-01-25
- Modified: 2025-04-01
- URL: https://entityrisk.com/webcasts/webcast-episode-1/
- Categories: Webcasts
---

- Published: 2023-01-07
- Modified: 2026-02-24
- URL: https://entityrisk.com/white-papers/white-paper-meeting-challenges-value-based-agreements/
- Categories: White Papers
---


---


## Team Members


---


## News and Events

- Published: 2025-08-18
- Modified: 2025-08-18
- URL: https://entityrisk.com/news_and_events/cleo-diagnostics-commences-health-economic-study-to-support-u-s-market-entry/
- News and Events Categories: News
---

- Published: 2025-02-26
- Modified: 2025-03-03
- URL: https://entityrisk.com/news_and_events/valuing-the-societal-impact-ofmedicines-and-other-healthtechnologies-a-user-guideto-current-best-practices/
- News and Events Categories: News
---

- Published: 2025-02-26
- Modified: 2025-03-03
- URL: https://entityrisk.com/news_and_events/jpmorgan-hosts-first-major-healthcare-gathering-since-death-of-united-healthcares-ceo/
- News and Events Categories: News
---

- Published: 2025-02-25
- Modified: 2025-03-03
- URL: https://entityrisk.com/news_and_events/medicare-drug-price-explanations-shed-some-light-on-future-talks/
- News and Events Categories: News
---

- Published: 2025-01-23
- Modified: 2025-03-03
- URL: https://entityrisk.com/news_and_events/medicare-drug-pricenegotiations-need-something-new-a-floor/
- News and Events Categories: News
---


---

> © 2026 EntityRisk. All rights reserved. For inquiries, visit https://entityrisk.com or contact us through the website. Content on this site reflects proprietary methodologies including the PROVEN™ platform. Unauthorized reproduction of modeling frameworks or scientific content is prohibited.


---